The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
30 November 2021 The US Court of Appeals for the Federal Circuit has affirmed a US Patent Trial and Appeal Board decision that held that claims of a patent for dissolvable films containing therapeutic agents were anticipated.
22 February 2019 Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.
5 February 2019 Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film following a ruling of the US Court of Appeals for the Federal Circuit.
